Total Payments
$9,941
2024 Payments
$2,687
Companies
48
Transactions
525
Medicare Patients
3,505
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$9,800 (98.6%)
Education$141.15 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,800 | 519 | 98.6% |
| Education | $141.15 | 6 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,978 | 132 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,033 | 63 | $0 (2024) |
| Janssen Biotech, Inc. | $1,022 | 50 | $0 (2024) |
| Celgene Corporation | $748.66 | 51 | $0 (2024) |
| BOSTON SCIENTIFIC CORPORATION | $713.02 | 13 | $0 (2021) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $598.40 | 36 | $0 (2024) |
| PFIZER INC. | $586.75 | 31 | $0 (2024) |
| Olympus America Inc. | $339.55 | 4 | $0 (2019) |
| IRONWOOD PHARMACEUTICALS, INC | $247.00 | 16 | $0 (2024) |
| QOL Medical, LLC | $236.69 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,687 | 134 | ABBVIE INC. ($525.33) |
| 2023 | $2,476 | 127 | AbbVie Inc. ($459.56) |
| 2022 | $1,234 | 78 | ABBVIE INC. ($371.43) |
| 2021 | $950.06 | 42 | BOSTON SCIENTIFIC CORPORATION ($314.19) |
| 2020 | $616.14 | 30 | Boston Scientific Corporation ($237.81) |
| 2019 | $890.77 | 62 | AbbVie, Inc. ($320.13) |
| 2018 | $530.01 | 23 | Olympus America Inc. ($149.93) |
| 2017 | $557.09 | 29 | Olympus America Inc. ($106.92) |
All Payment Transactions
525 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.57 | General |
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $26.55 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/13/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $7.54 | General |
| Category: Immunology | ||||||
| 12/12/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $11.62 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/10/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $32.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $28.46 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $32.41 | General |
| Category: Immunology | ||||||
| 11/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/21/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $29.26 | General |
| 11/19/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: LIVER DISEASE | ||||||
| 11/18/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $20.51 | General |
| Category: GI | ||||||
| 11/15/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $38.13 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.65 | General |
| Category: Immunology | ||||||
| 11/08/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $27.45 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/07/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $28.85 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $0.61 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/05/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $1.53 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 716 | 9,737 | $798,113 | $223,914 |
| 2022 | 19 | 1,028 | 19,727 | $1.7M | $451,796 |
| 2021 | 18 | 1,012 | 15,238 | $1.4M | $357,837 |
| 2020 | 19 | 749 | 7,689 | $704,810 | $193,804 |
Total Patients
3,505
Total Services
52,391
Medicare Billing
$1.2M
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 19 | 9,000 | $468,000 | $154,771 | 33.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 175 | 183 | $63,684 | $18,916 | 29.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 163 | 181 | $42,897 | $13,015 | 30.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 102 | 103 | $121,008 | $11,383 | 9.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 78 | 78 | $42,276 | $10,427 | 24.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 79 | 79 | $28,282 | $6,980 | 24.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 22 | 22 | $10,010 | $2,495 | 24.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 22 | 34 | $7,582 | $2,066 | 27.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 11 | $5,181 | $1,499 | 28.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 15 | $3,555 | $1,033 | 29.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 19 | 19 | $2,698 | $727.01 | 26.9% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 12 | 12 | $2,940 | $602.33 | 20.5% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2022 | 22 | 17,100 | $889,200 | $296,573 | 33.4% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 14 | 1,560 | $360,360 | $44,968 | 12.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 175 | 179 | $62,292 | $19,375 | 31.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 113 | 113 | $61,246 | $15,928 | 26.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 199 | 214 | $50,718 | $14,989 | 29.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 171 | 171 | $61,218 | $14,649 | 23.9% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2022 | 13 | 13 | $37,895 | $9,835 | 26.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 67 | 68 | $76,432 | $7,835 | 10.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 29 | 65 | $14,495 | $4,345 | 30.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 16 | 27 | $27,000 | $3,674 | 13.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 19 | 19 | $12,730 | $3,345 | 26.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 19 | $8,949 | $2,991 | 33.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 31 | 38 | $9,006 | $2,399 | 26.6% |
About Dr. Mahmood Abedi, MD
Dr. Mahmood Abedi, MD is a Gastroenterology healthcare provider based in Fairfax, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1649255233.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mahmood Abedi, MD has received a total of $9,941 in payments from pharmaceutical and medical device companies, with $2,687 received in 2024. These payments were reported across 525 transactions from 48 companies. The most common payment nature is "Food and Beverage" ($9,800).
As a Medicare-enrolled provider, Abedi has provided services to 3,505 Medicare beneficiaries, totaling 52,391 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Fairfax, VA
- Active Since 12/07/2005
- Last Updated 05/07/2019
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1649255233
Products in Payments
- ENTYVIO (Biological) $775.64
- ZEPOSIA (Drug) $757.42
- RINVOQ (Biological) $543.42
- STELARA (Biological) $485.49
- Humira (Biological) $450.25
- XIFAXAN (Drug) $442.12
- XELJANZ (Drug) $365.57
- EXALT (Device) $314.19
- TREMFYA (Drug) $294.29
- REMICADE (Biological) $285.98
- LINZESS (Drug) $253.48
- Linzess (Drug) $225.54
- ZENPEP (Drug) $220.76
- CREON (Drug) $203.39
- VIBERZI (Drug) $194.85
- HUMIRA (Biological) $194.76
- EXALT MODEL D CONTROLLER (Device) $181.88
- EVIS EXERA (Device) $176.50
- TRULANCE (Drug) $166.37
- VELSIPITY (Drug) $154.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Fairfax
Dr. Ali Siddiqui, Md, MD
Gastroenterology — Payments: $200,158
Gastroenterology $200,158
Dr. Michael Garone, M.d, M.D
Gastroenterology — Payments: $50,484
Gastroenterology $50,484
Asma Khapra
Gastroenterology — Payments: $24,933
Gastroenterology $24,933
Dr. Jeremias Tan, M.d, M.D
Gastroenterology — Payments: $16,746
Gastroenterology $16,746
Dr. Richard Blosser, M.d, M.D
Gastroenterology — Payments: $15,267
Gastroenterology $15,267
Dr. Tonya Adams, M.d, M.D
Gastroenterology — Payments: $13,340
Gastroenterology $13,340